journal article·2023-02Open access

Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma

Zhiying Zheng, Mingxi Ma, Xiuping Han, Xiao Li, Jinxin Huang, Yuetong Zhao, Hanyuan Liu, Junwei Kang, Xiangyi Kong, Guoqiang Sun, Guangshun Sun, Jie Kong, Weiwei Tang, Guoqiang Shao, Fei Xiong, Jinhua Song

Acta Biomaterialia· Volume 157

Abstract

Transarterial chemoembolization (TACE) is an image-guided locoregional therapy used for the treatment of patients with primary hepatocellular carcinoma (HCC). However, conventional TACE formulations such as epirubicin-lipiodol emulsion are rapidly dissociated due to the instability of the emulsion, resulting in insufficient local drug concentrations in the target tumor. To overcome these limitations, we used biodegradable Idarubicin loaded microspheres (BILMs), which were prepared from gelatin and carrageenan and could be loaded with Idarubicin (IDA-MS). The morphology and the ability to load and release IDA of BILMs were characterized in vitro. We evaluated tumor changes and side effects after TACE treatment with IDA-MS in VX2 rabbit and C57BL/6 mice HCC models. In addition, the effect of IDA-MS on the tumor immune microenvironment of HCC tumors was elucidated via mass spectrometry and immunohistochemistry. Result showed that IDA-MS was developed as a new TACE formulation to overcome the poor delivery of drugs due to rapid elimination of the anticancer drug into the systemic circulation. We demonstrated in rabbits and mice HCC models that TACE with IDA-MS resulted in significant tumor shrinkage and no more severe adverse events than those observed in the IDA group. TACE with IDA-MS could also significantly enhance the sensitivity of anti-PD1 immunotherapy, improve the expression of CD8+ T cells, and activate the tumor immune microenvironment in HCC. This study provides a new approach for TACE therapy and immunotherapy and illuminates the future of HCC treatment. Conventional transarterial chemoembolization (TACE) formulations are rapidly dissociated due to the instability of the emulsion, resulting in insufficient local drug concentrations in hepatocellular carcinoma (HCC). To overcome these limitations, we used biodegradable microspheres called BILMs, which could be loaded with Idarubicin (IDA-MS). We demonstrated in rabbits and mice HCC models that TACE with IDA-MS resulted in significant tumor shrinkage and no more severe adverse events than those observed in the IDA group. TACE with IDA-MS could also significantly enhance the sensitivity of anti-PD1 immunotherapy, improve the expression of CD8+ T cells, and activate the tumor immune microenvironment in HCC. This study provides a new approach for TACE therapy and immunotherapy and illuminates the future of HCC treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Hepatocellular Carcinoma Treatment and Prognosis · Multiple Myeloma Research and Treatments · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (54)

Show source-provided references
1. Pros and cons of portal vein embolization with hematopoietic stem cells application in colorectal liver metastases surgery10.21873/invivo.12121 ↗
2. Portal vein embolization does not affect the long-term survival and risk of cancer recurrence among colorectal liver metastases patients: a prospective cohort study10.1016/j.ijsu.2018.11.029 ↗
3. Improving the safety of major resection for hepatobiliary malignancy: portal vein embolization and recent innovations in liver regeneration strategies10.1007/s11912-020-00922-x ↗
4. Emerging therapies for hepatocellular carcinoma (HCC)10.3390/cancers14112798 ↗
5. Image-guided therapies in the treatment of hepatocellular carcinoma: a multidisciplinary perspective10.4254/wjh.v7.i2.235 ↗
6. Correlation of doxorubicin delivery and tumor necrosis after drug-eluting bead transarterial chemoembolization of rabbit VX2 liver tumors10.1148/radiol.2016152099 ↗
7. Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model10.7150/thno.32943 ↗
8. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival10.1053/jhep.2003.50047 ↗
9. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE)10.7150/thno.8725 ↗
10. Immunotherapeutic approaches for hepatocellular carcinoma10.18632/oncotarget.15406 ↗
11. Locoregional and systemic therapy for hepatocellular carcinoma10.21037/jgo.2017.03.13 ↗
12. Evaluation of immune-modulating drugs for use in drug-eluting microsphere transarterial embolization10.1016/j.ijpharm.2022.121466 ↗
13. MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL110.1053/j.gastro.2019.01.252 ↗
14. Stability of a high-concentrated aqueous solution of idarubicin stored in a polypropylene syringe for transarterial chemoembolization10.1016/j.jpba.2021.114543 ↗
15. Bench-to-clinic development of imageable drug-eluting embolization beads: finding the balance10.2217/fon-2018-0196 ↗
16. Cone-beam computed tomography-based spatial prediction of drug dose after transarterial chemoembolization using radiopaque drug-eluting beads in woodchuck hepatocellular carcinoma10.1097/RLI.0000000000000864 ↗
17. Synthesis, characterization, and imaging of radiopaque bismuth beads for image-guided transarterial embolization10.1038/s41598-020-79900-z ↗
18. A novel inherently radiopaque bead for transarterial embolization to treat liver cancer - a pre-clinical study10.7150/thno.13137 ↗
19. Characterization of a novel intrinsically radiopaque Drug-eluting Bead for image-guided therapy: DC Bead LUMI™10.1016/j.jconrel.2017.02.001 ↗
20. Development of biodegradable radiopaque microsphere for arterial embolization-a pig study10.4329/wjr.v7.i8.212 ↗
21. Fabrication of radiopaque drug-eluting beads based on lipiodol/biodegradable-polymer for image-guided transarterial chemoembolization of unresectable hepatocellular carcinoma10.1016/j.polymdegradstab.2020.109106 ↗
22. Polymeric materials for embolic and chemoembolic applications10.1016/j.jconrel.2016.02.033 ↗
23. Carrageenans for tissue engineering and regenerative medicine applications: a review10.1016/j.carbpol.2021.119045 ↗
24. Photocrosslinkable kappa-carrageenan hydrogels for tissue engineering applications10.1002/adhm.201200317 ↗
25. Carrageenan hydrogel as a scaffold for skin-derived multipotent stromal cells delivery10.1177/0885328218795569 ↗
26. Printed ionic-covalent entanglement hydrogels from carrageenan and an epoxy amine10.1039/C4RA07109C ↗
27. A biodegradable multifunctional porous microsphere composed of carrageenan for promoting imageable trans-arterial chemoembolization10.1016/j.ijbiomac.2019.10.026 ↗
28. Pentoxifylline affects idarubicin binding to DNA10.1016/j.bioorg.2016.02.005 ↗
29. An in vitro evaluation of four types of drug-eluting embolics loaded with idarubicin10.1016/j.jvir.2018.12.022 ↗
30. Idarubicin-loaded beads for chemoembolization of hepatocellular carcinoma: the IDASPHERE II single-arm phase II trial10.1148/radiol.2019182399 ↗
31. Liver chemoembolization of hepatocellular carcinoma using TANDEM® microspheres10.2217/fon-2018-0237 ↗
32. A novel resorbable embolization microsphere for transient uterine artery occlusion: a comparative study with trisacryl-gelatin microspheres in the sheep model10.1016/j.jvir.2014.06.025 ↗
33. Biodegradable poly(lactide-co-glycolide) microspheres encapsulating hydrophobic contrast agents for transarterial chemoembolization10.1080/09205063.2021.1990472 ↗
34. Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro:in-vivo correlation10.1007/s10856-006-0040-y ↗
35. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma10.1016/j.jhep.2012.07.017 ↗
36. Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial10.1111/apt.12746 ↗
37. Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres® beads in Chinese hepatocellular carcinoma patients10.1186/s12885-018-4566-4 ↗
38. Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: proof of concept using idarubicin10.1007/s00330-015-3855-4 ↗
39. Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma10.1097/CAD.0b013e328346a0c5 ↗
40. Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma10.3748/wjg.v26.i3.324 ↗
41. Vandetanib-eluting radiopaque beads: pharmacokinetics, safety, and efficacy in a rabbit model of liver cancer10.1148/radiol.2019190305 ↗
42. Highly tumor-specific and long-acting iodine-131 microbeads for enhanced treatment of hepatocellular carcinoma with low-dose radio-chemoembolization10.1021/acsnano.0c09122 ↗
43. Biodegradable and multifunctional microspheres for treatment of hepatoma through transarterial embolization10.1021/acsbiomaterials.8b00635 ↗
44. Vandetanib-eluting radiopaque beads: in vivo pharmacokinetics, safety and toxicity evaluation following swine liver embolization10.7150/thno.19652 ↗
45. Arming embolic beads with anti-VEGF antibodies and controlling their release using LbL technology10.1016/j.jconrel.2016.01.010 ↗
46. Zamorano · Eur. Heart J. · 2016 · 37 · 276810.1093/eurheartj/ehw211 ↗
47. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial10.1016/j.jhep.2016.01.012 ↗
48. Idarubicin-loaded ONCOZENE drug-eluting bead chemoembolization in a rabbit liver tumor model: investigating safety, therapeutic efficacy, and effects on tumor microenvironment10.1016/j.jvir.2020.04.010 ↗
49. Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience10.1007/s00270-012-0532-8 ↗
50. Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: the LIDA-B phase I trial10.1016/j.jhep.2018.01.022 ↗
51. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial10.1016/S0140-6736(17)31046-2 ↗
52. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial10.1016/S1470-2045(20)30011-5 ↗
53. IMbrave150 investigators. atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma10.1056/NEJMoa1915745 ↗
54. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients10.1038/nature14011 ↗